NewLink Genetics to Participate in the Cantor Global Healthcare Conference

AMES, Iowa, Sept. 18, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation NLNK announced today that the Company will present at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018, at 4:00PM ET in New York, New York.

A live webcast of the presentation will be available on the Company's website at www.newlinkgenetics.com in the "Investors & Media" section under "Events and Presentations." An archived edition of the presentation will be available on NewLink Genetics' website later that day.

About NewLink Genetics Corporation

NewLink Genetics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' leading drug candidate, indoximod, is an investigational, orally available small molecule designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.

Investor Contact:

Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
lmiller@linkp.com

Media Contact:

Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
scorreia@lavoiehealthscience.com